ProPhase Labs Uplists from Pink Sheets to OTC Market

Rhea-AI Summary

ProPhase Labs (OTC: PRPH) announced that its common stock was approved and uplisted from the Pink Sheets to the OTC market on January 22, 2026. The company said it expects the coming weeks to be an important inflection point and highlighted continued momentum in its Crown Medical collections initiative. ProPhase said it will provide a near-term operational update on Crown Medical and a strategic update on its BE-Smart® Esophageal Cancer Test. Management reiterated focus on executing core businesses and strengthening the company’s financial position to drive long-term shareholder value.

Positive

• Uplist approved to OTC market on Jan 22, 2026
• Management cites momentum in Crown Medical collections initiative
• Near-term strategic update planned for BE-Smart Esophageal Cancer Test

Negative

• None.

News Market Reaction

+53.03%

1 alert

+53.03% News Effect

On the day this news was published, PRPH gained 53.03%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Announcement date: Jan. 22, 2026

1 metrics

Announcement date Jan. 22, 2026 Publication date of uplisting news

Market Reality Check

Price: $0.2578 Vol: Volume 176,829 is low wit...

low vol

$0.2578 Last Close

Volume Volume 176,829 is low with volume_relative at 0.15x the 20-day average 1,158,712. low

Technical Shares at 0.1401 are trading below the 200-day MA of 3.13 and far below the 52-week high of 7.8.

Peers on Argus

Peers show mixed moves: several are down (e.g., ADVB -6.66%, ISPC -4.11%, PRPO -...

1 Up 1 Down

Peers show mixed moves: several are down (e.g., ADVB -6.66%, ISPC -4.11%, PRPO -0.84%, BIAF -0.76%) while NOTV is up 0.82%. Momentum scanner shows MYNZ up 5.93% and XWEL down 17.90%, reinforcing that this looks stock-specific rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Capital structure update	Positive	-22.8%	Detailed debt conversions, reverse split and OTC move to stabilize balance sheet.
Dec 19	Reverse merger LOI	Positive	-14.7%	Outlined proposed reverse merger, implied $30M value and potential special dividend.
Dec 19	LOI counterparty update	Neutral	-14.7%	ABL Diagnostics described non‑binding LOI terms and regulatory, timing conditions.
Nov 26	Investor webinar	Positive	+0.7%	Announced webinar to discuss portfolio, BE‑Smart test and Crown collections initiative.
Nov 19	Q3 2025 earnings	Negative	-9.5%	Reported lower revenue, significant net loss and tight cash with high liabilities.

Pattern Detected

Recent history shows several ostensibly positive or strategic updates followed by notable negative price reactions, suggesting a pattern where the stock has often sold off on news.

Recent Company History

Over the last few months, ProPhase Labs has focused on capital structure repair and strategic repositioning. On Nov 19, 2025, it reported Q3 revenue of $0.9M and a net loss of $6.8M, alongside tight liquidity. Subsequent releases highlighted a 1-for-10 reverse split, work on $50M+ Crown Medical collections, and a proposed reverse merger with Advanced Biological Laboratories implying up to $30M enterprise value and a potential $10M special dividend. A January 2026 update detailed >$3.3M of convertible debt conversions and transition to OTC, setting the stage for today’s uplisting announcement.

Market Pulse Summary

The stock surged +53.0% in the session following this news. A strong positive reaction aligns with m...

Analysis

The stock surged +53.0% in the session following this news. A strong positive reaction aligns with management’s effort to rebuild credibility after recent balance-sheet stress, reverse split, and transition to OTC. Historically, some constructive updates still saw declines, so a large gain would mark a break from that pattern. Investors would need to watch execution on Crown Medical collections and BE‑Smart commercialization, as well as any future capital-structure actions, when judging the durability of a move of 5%+ or more.

Key Terms

pink sheets, otc market, esophageal cancer

3 terms

pink sheets financial

"its common stock has been approved and uplisted from the Pink Sheets to the OTC market"

Pink sheets are stocks traded over-the-counter on informal quotation lists rather than on major exchanges; they often include small, thinly traded, or less-regulated companies. Think of them as a neighborhood garage sale compared with a big retail store: prices can jump or vanish quickly, public information may be limited, and trading is riskier and less liquid, so investors should expect higher volatility and greater chance of losing money.

otc market financial

"approved and uplisted from the Pink Sheets to the OTC market"

A marketplace where securities are bought and sold directly between dealers or brokers rather than on a formal stock exchange; think of it as a flea market for stocks and bonds instead of a supermarket. It matters to investors because these trades often involve smaller or less-regulated companies, so prices can swing more, information can be scarcer, and it may be harder to quickly buy or sell — offering both higher risk and potential opportunity.

esophageal cancer medical

"strategic update on our BE-Smart® Esophageal Cancer Test in the near term"

Esophageal cancer is a disease in which abnormal cells grow uncontrollably in the esophagus, the muscular tube that carries food from the throat to the stomach. Think of it as a blockage or damage forming inside a pipe that can disrupt function and require surgery, drugs, or medical devices. Investors care because its incidence, treatment advances, clinical trial results and regulatory approvals directly affect demand, costs, company revenues and valuations in healthcare markets.

AI-generated analysis. Not financial advice.

UNIONDALE, NY, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (“ProPhase” or the “Company”), a diversified life sciences and diagnostics company, today announced that its common stock has been approved and uplisted from the Pink Sheets to the OTC market.

“We are pleased to have completed this uplisting from the Pink Sheets to the OTC market,” said Ted Karkus, Chairman and Chief Executive Officer of ProPhase Labs. “We believe the coming weeks will mark an important inflection point for ProPhase Labs. We continue to see encouraging momentum in our Crown Medical collections initiative, and we plan to provide a positive operational update on that effort very shortly. We also plan to provide a strategic update on our BE-Smart® Esophageal Cancer Test in the near term.”

ProPhase Labs remains focused on executing across its core businesses, strengthening its financial position, and advancing initiatives intended to drive long-term shareholder value.

About ProPhase Labs Inc.

ProPhase Labs Inc. (OTC: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world-class direct-to-consumer marketing platform for cutting-edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value.
www.ProPhaseLabs.com

Forward-Looking Statements

Except for the historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our expectations regarding the future revenue growth potential of each of our subsidiaries, our expected timeline for commercializing our BE-Smart Esophageal Cancer Test, our expectations regarding future liquidity events, the success of our efforts to collect accounts receivables and anticipated timeline for any payments relating thereto, and our ability to successfully transition into a consumer products company. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially. Details about these risks and uncertainties can be found in our filings with the SEC. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Investor Relations Contact:

Dave Gentry, CEO
RedChip Companies, Inc.
1-800-REDCHIP (733-2447)
1-407-644-4256
PRPH@redchip.com

Retail Investor Relations Contact:

Renmark Financial Communications
John Boidman: jboidman@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

FAQ

What did ProPhase Labs (PRPH) announce on January 22, 2026?

ProPhase announced approval to uplist its common stock from the Pink Sheets to the OTC market on January 22, 2026.

How might the PRPH uplisting to the OTC market affect shareholders?

The company expects the uplisting to mark an important inflection point and to potentially improve visibility and trading on the OTC market.

When will ProPhase (PRPH) provide updates on Crown Medical and BE-Smart test?

ProPhase said it will provide a near-term operational update on Crown Medical and a strategic update on the BE-Smart Esophageal Cancer Test in the coming weeks.

Does the Jan 22, 2026 announcement include financial results for PRPH?

No; the announcement did not include earnings, revenue, or other financial figures.

What business areas did ProPhase highlight in the PRPH announcement?

ProPhase highlighted its Crown Medical collections initiative and the BE-Smart Esophageal Cancer Test while reaffirming focus on core businesses and financial strength.

What ticker should investors use to trade ProPhase after the uplisting?

Investors should refer to PRPH trading on the OTC market following the Jan 22, 2026 approval.